BARBERA MARIA CHIARA
Pubblicazioni
Petrella, S., Colombo, M., Marabese, M., Grasselli, C., Panfili, A., Chiappa, M., et al. (2025). Onvansertib and Navitoclax Combination as a New Therapeutic Option for Mucinous Ovarian Carcinoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 26(2) [10.3390/ijms26020472]. Dettaglio
Barbera, M., Guarrera, L., Re Cecconi, A., Cassanmagnago, G., Vallerga, A., Lunardi, M., et al. (2025). Increased ectodysplasin-A2-receptor EDA2R is a ubiquitous hallmark of aging and mediates parainflammatory responses. NATURE COMMUNICATIONS, 16(1) [10.1038/s41467-025-56918-3]. Dettaglio
Petrella, S., Colombo, M., Marabese, M., Grasselli, C., Panfili, A., Craparotta, I., et al. (2024). Abstract 4685: The identification of new therapeutic targets in mucinous ovarian carcinoma. In Proceedings: AACR Annual Meeting 2024; April 5-10, 2024; San Diego, California; Part 1 (Regular Abstracts) [10.1158/1538-7445.am2024-4685]. Dettaglio
Chiappa, M., Decio, A., Guarrera, L., Mengoli, I., Karki, A., Yemane, D., et al. (2024). Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas. CELL DEATH & DISEASE, 15(7) [10.1038/s41419-024-06894-1]. Dettaglio
Riva, A., Sahin, E., Volpedo, G., Petretto, A., Lavarello, C., Di Sapia, R., et al. (2024). Identification of an epilepsy-linked gut microbiota signature in a pediatric rat model of acquired epilepsy. NEUROBIOLOGY OF DISEASE, 194(May 2024) [10.1016/j.nbd.2024.106469]. Dettaglio